Patents by Inventor Yannis Morel
Yannis Morel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240392008Abstract: Multispecific proteins that bind NKp46 and specifically redirect effector cells to lyse a target cell of interest via multiple receptors are provided. The proteins have utility in the treatment of disease, notably cancer or infectious disease.Type: ApplicationFiled: June 8, 2022Publication date: November 28, 2024Inventors: Laurent GAUTHIER, Yannis MOREL, Olivier DEMARIA
-
Publication number: 20240199750Abstract: Multi-specific proteins that bind to NKp46 and a cytokine receptor on NK cells, and optionally that further bind CD16A on NK cells, and that also bind to an antigen of interest (e.g. a cancer antigen) on a target cell (e.g. a cancer cell). The multi-specific proteins are capable of increasing NK cell cytotoxicity toward a target cell that expresses the antigen of interest (e.g., a cell that contributes to disease, a cancer cell).Type: ApplicationFiled: March 24, 2022Publication date: June 20, 2024Inventors: Stephanie CORNEN, Laurent GAUTHIER, Yannis MOREL, Olivier DEMARIA
-
Patent number: 9944712Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.Type: GrantFiled: May 30, 2013Date of Patent: April 17, 2018Assignee: Innate PharmaInventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
-
Patent number: 9828427Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.Type: GrantFiled: October 28, 2015Date of Patent: November 28, 2017Assignee: INNATE PHARMAInventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi
-
Publication number: 20160347853Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.Type: ApplicationFiled: July 7, 2016Publication date: December 1, 2016Inventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel
-
Patent number: 9388246Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.Type: GrantFiled: May 5, 2011Date of Patent: July 12, 2016Assignee: INNATE PHARMAInventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel
-
Publication number: 20160046713Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.Type: ApplicationFiled: October 28, 2015Publication date: February 18, 2016Inventors: NICOLAS ANFOSSI, LAURENT GAUTHIER, YANNIS MOREL, ALESSANDRO MORETTA, SILVIA PAROLINI, BENJAMIN ROSSI
-
Patent number: 9181341Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.Type: GrantFiled: January 15, 2010Date of Patent: November 10, 2015Assignee: INNATE PHARMAInventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi
-
Publication number: 20150140000Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.Type: ApplicationFiled: May 30, 2013Publication date: May 21, 2015Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
-
Publication number: 20140234323Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: ApplicationFiled: May 2, 2014Publication date: August 21, 2014Applicant: Innate PharmaInventors: KARINE CHEMIN, LAURENT GAUTHIER, YANNIS MOREL, CARINE PATUREL, AGNES TISSERANT
-
Patent number: 8715667Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: GrantFiled: August 15, 2012Date of Patent: May 6, 2014Assignee: Innate PharmaInventors: Karine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Publication number: 20140065154Abstract: The invention provides anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.Type: ApplicationFiled: January 10, 2012Publication date: March 6, 2014Applicant: INNATE PHARMAInventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel, Cecile Bonnafous, Mette Dahl Andersen, Benjamin Rossi
-
Publication number: 20120308581Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: ApplicationFiled: August 15, 2012Publication date: December 6, 2012Applicant: INNATE PHARMAInventors: KARINE CHEMIN, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Patent number: 8273541Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: GrantFiled: September 15, 2009Date of Patent: September 25, 2012Assignee: Innate PharmaInventors: Karine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Publication number: 20120064081Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.Type: ApplicationFiled: January 15, 2010Publication date: March 15, 2012Applicant: INNATE PHARMAInventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi
-
Publication number: 20120034232Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.Type: ApplicationFiled: May 5, 2011Publication date: February 9, 2012Applicant: Innate PharmaInventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel
-
Publication number: 20110212110Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: ApplicationFiled: September 15, 2009Publication date: September 1, 2011Inventors: Karine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Publication number: 20110076296Abstract: The present invention relates generally to the fields of medicine. More specifically, the present invention relates to improved TLR3 agonists. The present invention provides novel dsRNA such as polyAU composition useful in the treatment of TLR3 related diseases, uses and preparations thereof.Type: ApplicationFiled: April 22, 2009Publication date: March 31, 2011Applicant: INNATE PHARMA S.A.Inventors: Eric Aubin, Christian Belmant, Laurent Gauthier, Yannis Morel, Carine Paturel, Delphine Bregeon